Trachoma overview

Jump to navigation Jump to search

Trachoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Trachoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Trachoma overview On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Trachoma overview

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Trachoma overview

CDC on Trachoma overview

Trachoma overview in the news

Blogs on Trachoma overview

Directions to Hospitals Treating Trachoma

Risk calculators and risk factors for Trachoma overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Trachoma is an infectious eye disease, and the leading cause of the world’s preventable blindness.

Causes

Trachoma is caused by the bacteria Chlamydia trachomatis and it is spread by direct contact with eye, nose, and throat secretions from affected individuals, or contact with fomites (inanimate objects), such as towels and/or washcloths, that have had similar contact with these secretions.

Diagnosis

Physical Examination

An eye exam may reveal scarring on the inside of the upper eye lid, redness of the white part of the eyes, and new blood vessel growth into the cornea.

Treatment

Medical Therapy

Antibiotics can prevent long-term complications if used early in the infection. Antibiotics include erythromycin and doxycycline. In certain cases, eyelid surgery may be needed to prevent long-term scarring, which can lead to blindness if not corrected.

Cost-Effectiveness of Therapy

Globally this disease results in an estimated US $2.9 billion in lost productivity every year by affecting 84 million people from active infection and nearly 8 million people, who are visually impaired as a result of this disease.

References

Template:WH Template:WS